Cobicistat Patent Expiration
Cobicistat is Used for treating HIV infection by enhancing the pharmacokinetics and inhibiting cytochrome P450 monooxygenase. It was first introduced by Gilead Sciences Inc
Cobicistat Patents
Given below is the list of patents protecting Cobicistat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tybost |
US10039718 (Pediatric) | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Apr 06, 2033 | Gilead Sciences Inc |
| Tybost | US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Oct 06, 2032 | Gilead Sciences Inc |
| Tybost |
US8148374 (Pediatric) | Modulators of pharmacokinetic properties of therapeutics | Mar 03, 2030 | Gilead Sciences Inc |
| Tybost | US8148374 | Modulators of pharmacokinetic properties of therapeutics | Sep 03, 2029 | Gilead Sciences Inc |
Cobicistat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cobicistat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
